@seaporttx.bsky.socialSeaport Crew has been active: discussions on #neuropsychiatric drug development, IP, trends & scientific presentations. Our team’s leadership in the community - conferences, panels, & industry events, helps us share insights & best practices as we bring new medicines to patients.
@uoft-tcairem.bsky.social🇺🇸 #ArtificialIntelligence-Enabled Pharmacovigilance for #Neuropsychiatric Therapies: Advancing U.S. #Drug Safety Surveillance and Regulatory Decision-Making
@molneurodegenadvnc.bsky.socialQuantitative cellular morphology in #neurodegenerative and #neuropsychiatric diseases: insights into disease mechanisms and therapeutic discovery
Gautam Wali, Ratneswary Sutharsan, Helen Jones, Shubh Singh, Carolyn M. Sue #mitchondria #lysosome
@neurotherapytdy.bsky.socialDo anti-seizure medications increase the risk of #neuropsychiatric adverse events in #epilepsy? A new review explored links between ASM use and mood, #cognitive, behavioral, and psychotic disorders, with risk varying across therapies.#Neurology
Read more: www.docwirenews.com/post/do-anti...
@oae-evcna.bsky.social🧠 How can #stemcell-derived #extracellularvesicles advance therapies for #neuropsychiatric disorders?
This Review explores their neuroprotective mechanisms, therapeutic potential, and key challenges in clinical translation. 🔬
www.oaepublish.com/articles/evc...
@drwp.bsky.social @jdevos.bsky.social
